Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine
Saval Khanal, Martin Underwood, Seyran Naghdi, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
Andrew Charles, Kathleen B. Digre, Peter J. Goadsby, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 64, Iss. 4, pp. 333-341
Open Access | Times Cited: 65
Bridging Gaps in Migraine Management: A Comprehensive Review of Conventional Treatments, Natural Supplements, Complementary Therapies, and Lifestyle Modifications
Fatma Abo-Elghiet, Heba El-Osaily, Doha K. Hussein, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 139-139
Open Access | Times Cited: 1
Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis
Seyran Naghdi, Martin Underwood, Jason Madan, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
The Migraine Stigma Kaleidoscope View
Elena Groß, Elena Ruiz de la Torre, Paolo Martelletti
Neurology and Therapy (2023) Vol. 12, Iss. 3, pp. 703-709
Open Access | Times Cited: 15
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis
Patricia Pozo‐Rosich, José Luís Poveda, C. Crespo, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Treatment Patterns and Healthcare Resource Utilization by Gender and Migraine Frequency in Adult Patients Receiving Galcanezumab Versus Standard of Care Preventive Medications Over 24 months: A United States Retrospective Claims Study
Oralee J. Varnado, Michelle Vu, Erin Buysman, et al.
Patient Preference and Adherence (2025) Vol. Volume 19, pp. 543-567
Open Access
Pain interference and distress in chronic migraine: observing the influence of traumatic experiences through the lenses of the theory of mentalizing
Marco Cannavò, Janine Gullo, Giorgio Falgares, et al.
Psychology Health & Medicine (2025), pp. 1-15
Closed Access
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials
Marcello Silvestro, Ilaria Orologio, Mattia Siciliano, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 2, pp. 79-96
Closed Access | Times Cited: 11
Migraine headache (MH) classification using machine learning methods with data augmentation
Lal Khan, Moudasra Shahreen, Atika Qazi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management
Patricia Pozo‐Rosich, Alicia Alpuente, Stephen D. Silberstein, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 9, pp. 555-568
Closed Access | Times Cited: 3
Economic burden of chronic migraine in OECD countries: a systematic review
Alyaa Eltrafi, Sunil Shrestha, Ali Ahmed, et al.
Health Economics Review (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Competing treatments for migraine: a headache for decision-makers
Hema Mistry, Seyran Naghdi, Martin Underwood, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
Catherine C. Turkel, Sheena K. Aurora, Hans‐Christoph Diener, et al.
Medicine (2023) Vol. 102, Iss. S1, pp. e32600-e32600
Open Access | Times Cited: 7
New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication
Hans‐Christoph Diener, Arne May
Cephalalgia (2024) Vol. 44, Iss. 3
Open Access | Times Cited: 2
Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review
Seyran Naghdi, Martin Underwood, Anna Brown, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 1, pp. e000616-e000616
Open Access | Times Cited: 2
An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity
Edward Griffin, Gawain Shirley, Xin Ying Lee, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective
Takao Takeshima, Fumihiko Sakai, Xinyu Wang, et al.
PharmacoEconomics (2024) Vol. 42, Iss. 7, pp. 811-822
Open Access | Times Cited: 2
Multimodal digital health treatments for Chronic Migraine associated with Medication Overuse Headache: a literature appraisal and results of a single-arm open trial (the BE-HOME program)
Licia Grazzi, Danilo Antonio Montisano, Domenico D’Amico, et al.
Neurological Sciences (2024) Vol. 45, Iss. 10, pp. 4923-4930
Closed Access | Times Cited: 2
Predictors of galcanezumab response in a real-world study of Korean patients with migraine
Seung Ae Kim, Hyemin Jang, Mi Ji Lee
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study
Hsiangkuo Yuan, Fred Cohen, Maurice T. Driessen, et al.
Cephalalgia Reports (2024) Vol. 7
Open Access | Times Cited: 1
Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling
Hema Mistry, Seyran Naghdi, Anna Brown, et al.
Health Technology Assessment (2024), pp. 1-329
Open Access | Times Cited: 1
Combining onabotulinumtoxin A with a CGRP antagonist for chronic migraine prophylaxis: where do we stand?
Lanfranco Pellesi
Frontiers in Pain Research (2023) Vol. 4
Open Access | Times Cited: 3
Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States
Oralee J. Varnado, Wenyu Ye, Xiaojuan Mi, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 149-157
Open Access | Times Cited: 2
Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review
Délia Szok, Anett Csáti, László Vécsei, et al.
Life (2023) Vol. 13, Iss. 3, pp. 665-665
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top